Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Vertex Hep C Treatment Passes Midstage Milestone

March 31, 2011 7:19 am | News | Comments

Vertex Pharmaceuticals Inc. said that a potential hepatitis C treatment was safe and tolerable in a midstage study. The study involved a combination of telaprevir and VX-222 with pegylated-interferon and ribavirin.


Phase 3 Study Begins for ALS Treatment

March 31, 2011 7:17 am | News | Comments

Biogen Idec and Knopp Biosciences announced enrollment of the first patient in EMPOWER, a multi-national Phase 3 study evaluating the efficacy, safety and pharmacokinetics of dexpramipexole in patients with amyotrophic lateral sclerosis.


Researchers Make the Leap to Whole-Cell Simulations

March 31, 2011 7:10 am | News | Comments

Researchers have built a computer model of the crowded interior of a bacterial cell that, in a test of its response to sugar in its environment, accurately simulates the behavior of living cells.


Scientists Discover Crucial Trigger for Tumor Protein

March 31, 2011 7:01 am | News | Comments

Scientists have discovered an essential protein that controls inflammation induced by tumor necrosis factor (TNF), an important part of the body’s defences against infection and a driver of cancer-associated inflammation.


Analyst Lowers BMS Rating

March 31, 2011 6:53 am | News | Comments

Bristol-Myers Squibb Co. received some good news last week with the approval of its cancer treatment Yervoy, but at least one analyst believes the drugmaker now faces pressures that spare little room for near-term earnings momentum.


Medicare to Cover Pricy Prostate Drug

March 31, 2011 6:51 am | by Matthew Perrone | News | Comments

Medicare officials said that the program will pay the $93,000 cost of prostate cancer drug Provenge, an innovative therapy that typically gives men suffering from an incurable stage of the disease an extra four months to live.


J & J Reorganizing Embattled Consumer Business

March 31, 2011 6:49 am | News | Comments

Johnson & Johnson said that it is reorganizing its consumer business, including giving more attention to its McNeil Consumer Healthcare unit, which has been stung by around 20 recalls of popular over-the-counter products like Tylenol, Motrin, and Benadryl.


Clinical Trial Electronic Data Capture Solutions: Elevating Efficiency and Insight

March 31, 2011 6:29 am | by Simon Brooks, Senior Director Product Strategy, Oracle Health Sciences | Articles | Comments

The clinical trial process has reached new levels of complexity. Trials are longer, more expansive, more complex in design, increasingly global, and require new types of data.


Advanced Software for Data Management and Mining

March 31, 2011 5:57 am | by Derrick Snyder, NI DataFinder Product Manager; National Instruments, Austin, Texas | Articles | Comments

High-level software tools such as the Data Acquisition Assistant in National Instruments’ LabVIEW allow scientists and engineers to rapidly interface with hardware and reduce the time it takes to make complex measurements.



March 30, 2011 7:59 am | Product Releases | Comments

Konica Minolta Sensing Americas, Inc. announces the launch of its next generation color measurement instrument, the CM-5 Spectrophotometer, to the pharmaceutical industry at the 2011 Interphex show.


Migration Assay Kit

March 30, 2011 7:55 am | Product Releases | Comments

EMD Millipore announced the introduction of the Millicell µ-Migration Assay Kit. This slide-based platform can be used to visualize and measure the effects of chemoattractants on the migration of adherent cells in real time.


Merck Strengthens Research Cooperation With Israel

March 30, 2011 7:46 am | News | Comments

Merck KGaA announced the initiation of a Merck Serono Israel Bioincubator Fund, a strategic and corporate initiative targeting Israeli biotechnology start-ups.


Almac Opens CLIA Laboratory

March 30, 2011 7:43 am | News | Comments

Almac’s Diagnostics business unit announced the opening of its CLIA registered laboratory. The opening of the Almac CLIA Laboratory supports the company’s ongoing diomarker discovery and development strategy.


Cancer Is a p53 Protein Aggregation Disease

March 30, 2011 7:30 am | News | Comments

Protein aggregation, generally associated with Alzheimer's and mad cow disease, turns out to play a significant role in cancer. Certain mutations of p53 cause the protein to misfold in a way that the proteins start to aggregate.


Antioxidant Formula Reduces Radiation Damage

March 30, 2011 7:27 am | News | Comments

A unique formulation of antioxidants taken orally before imaging with ionizing radiation minimizes cell damage. As much as a 50% reduction in DNA injury was observed after administering the formula prior to CT scans.



You may login with either your assigned username or your e-mail address.
The password field is case sensitive.